Pemphigoid diseases: Pathogenesis, diagnosis, and treatment

Autoimmunity

Volumn 45, Issue 1, 2012, Pages 55-70

  Kasperkiewicz, Michael ^a   Zillikens, Detlef ^a   Schmidt, Enno ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Antibody; Antigen; Pemphigoid; Skin

Indexed keywords

AZATHIOPRINE; BULLOUS PEMPHIGOID ANTIGEN 1; CLOBETASOL PROPIONATE; CORTICOSTEROID; DAPSONE; GELATINASE B; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE PROTEIN; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMALIZUMAB; PREDNISOLONE; PREDNISONE; PROTEIN BP180; RITUXIMAB; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTI P200 PEMPHIGOID; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BULLOUS PEMPHIGOID; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KERATINOCYTE; LICHEN PLANUS; LICHEN PLANUS BULLOSUS; LINEAR IMMUNOGLOBULIN A DERMATOSIS; LOW DRUG DOSE; MORNING DOSAGE; MUCOUS MEMBRANE PEMPHIGOID; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PLASMAPHERESIS; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SKIN DISEASE; T LYMPHOCYTE; TH2 CELL; TREATMENT DURATION; WESTERN BLOTTING;

HUMANS; SKIN DISEASES, VESICULOBULLOUS;

EID: 84856421317     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.606447     Document Type: Review

References (189)

1. Bertram F, Bröcker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009;7: 434-440.
2. Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, Borradori L. Autoimmune bullous disease Swiss study group. Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. Br J Dermatol 2009; 161:861-868.
3. Cozzani E, Parodi A, Rebora A, Delmonte S, Barile M, Nigro A, Priano L, Troiano G, Patri PL, Gruppo Ligure di Studi in Dermatologia (GLISID). Bullous pemphigoid in Liguria: A 2-year survey. J Eur Acad Dermatol Venereol 2001;15: 317-319.
4. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, Ormerod AD. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005;153:424-427. (Pubitemid 41228445)
5. Serwin AB, Bokiniec E, Piascik M, Masny D, Chodynicka B. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. Med Sci Monit 2007; 13:CR360-CR364. (Pubitemid 47359103)
6. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: Population based cohort study. BMJ 2008;337:160-163. doi: 10.1136/bmj.a180. (Pubitemid 352039867)
7. Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010;10:84-89.
8. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified epithelia. Cell 1981;24:897-903. (Pubitemid 11071328)
9. Mutasim DF, Takahashi Y, Labib RS, Anhalt GJ, Patel HP, Diaz LA. A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeletonhemidesmosome complex. J Invest Dermatol 1985;84: 47-53. (Pubitemid 15186224)
10. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA. Molecular heterogeneity of bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986;136: 1231-1235. (Pubitemid 16156221)
11. Tanaka M, Hashimoto T, Amagai M, Shimizu N, Ikeguchi N, Tsubata T, Hasegawa A, Miki K, Nishikawa T. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 1991;97:725-728.
12. Sawamura D, Li K, Chu ML, Uitto J, Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 1991; 266:17784-17790. (Pubitemid 21908010)
13. Green KJ, Virata ML, Elgart GW, Stanley JR, Parry DA. Comparative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: Members of a new gene family involved in organization of intermediate filaments. Int J Biol Macromol 1992;14:145-153.
14. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992;99:243-250.
15. Li K, Tamai K, Tan EM, Uitto J, Cloning of type XVII collagen. Complementary and genomic DNA sequences of mouse 180-kilodalton bullous pemphigoid antigen (BPAG2) predict an interrupted collagenous domain, a transmembrane segment, and unusual features in the 50-end of the gene and the 30-untranslated region of the mRNA. J Biol Chem 1993; 268:8825-8834. (Pubitemid 23118673)
16. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993;151:5742-5750. (Pubitemid 23332383)
17. Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997a;109:573-579. (Pubitemid 27433604)
18. ZillikensD, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, Hoffmann RG, Diaz LA, Giudice GJ. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997b;109:679-683. (Pubitemid 27465925)
19. Sitaru C, Dähnrich C, Probst C, Komorowski L, Blöcker I, Schmidt E, SchlumbergerW, Rose C, StöckerW, ZillikensD. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007;16:770-777. (Pubitemid 47261869)
20. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000;136: 174-178. (Pubitemid 30090755)
21. Zimina EP, Fritsch A, Schermer B, Bakulina AY, Bashkurov M, Benzing T, Bruckner-Tuderman L. Extracellular phosphorylation of collagen XVII by ectocasein kinase 2 inhibits ectodomain shedding. J Biol Chem 2007;282:22737-22746. (Pubitemid 47267317)
22. Zimina EP, Hofmann SC, Fritsch A, Kern JS, Sitaru C, Bruckner-Tuderman L. Bullous pemphigoid autoantibodies preferentially recognize phosphoepitopes in collagen XVII. J Invest Dermatol 2008;128:2736-2739.
23. Leyendeckers H, Tasanen K, Bruckner-Tuderman L, Zillikens D, Sitaru C, Schmitz J, Hunzelmann N. Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 2003;120: 372-378. (Pubitemid 36298422)
24. + plasma cells in the peripheral blood of patients with bullous pemphigoid: NC16a-specific cells belong to the short-lived plasma blast population. J Invest Dermatol 2010;130:2838-2841.
25. Bernard P, Aucouturier P, Denis F, Bonnetblanc JM. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol 1990;54:484-494. (Pubitemid 20088578)
26. Döpp R, Schmidt E, Chimanovitch I, Leverkus M, Bröcker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000;42:577-583. (Pubitemid 30479879)
27. Laffitte E, Skaria M, Jaunin F, Tamm K, Saurat JH, Favre B, Borradori L. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br J Dermatol 2001; 144:760-768. (Pubitemid 32374778)
28. Dimson OG, Giudice GJ, Fu CL, Van den Bergh F, Warren SJ, Janson MM, Fairley JA. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003;120:784-788. (Pubitemid 36529079)
29. Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, Hara T, Muroi E, Ogawa F, Takenaka M, Sato S. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008;144:41-48. (Pubitemid 351159388)
30. Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 2005;125:467-472.
31. Giudice GJ, Wilske KC, Anhalt GJ, Fairley JA, Taylor AF, Emery DJ, Hoffman RG, Diaz LA. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994; 102:878-881. (Pubitemid 24210382)
32. Perriard J, Jaunin F, Favre B, Büdinger L, Hertl M, Saurat JH, Borradori L. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol 1999;112:141-147. (Pubitemid 29061967)
33. Di Zenzo G, Grosso F, Terracina M, Mariotti F, De Pità O, Owaribe K, Mastrogiacomo A, Sera F, Borradori L, Zambruno G. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004;122:103-110. (Pubitemid 38114646)
34. Dresow SK, Sitaru C, Recke A, Oostingh GJ, Zillikens D, Gibbs BF. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009;160:429-432.
35. Skaria M, Jaunin F, Hunziker T, Riou S, Schumann H, Bruckner-Tuderman L, Hertl M, Bernard P, Saurat JH, Favre B, Borradori L. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. J Invest Dermatol 2000; 114:998-1004. (Pubitemid 30252723)
36. Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004;111:146-152. (Pubitemid 38482094)
37. Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P, Treudler R, Zouboulis CC, Schuler G, Borradori L, Hertl M. BP230-and BP180-specific autoantibodies in bullous pemphigoid. J Invest Dermatol 2004; 122:1413-1422. (Pubitemid 38757223)
38. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, Sebbag N, Pedicelli C, Sera F, Lacour JP, Wieslander J, Bruckner-Tuderman L, Borradori L, Zambruno G, Hertl M. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008;128:415-426.
39. Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C, Tabary T, Grange F, Bernard P. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of Bullous Pemphigoid: A retrospective study of 138 patients. Arch Dermatol 2011;147:286-291.
40. Roussel A, Benichou J, Randriamanantany ZA, Gilbert D, Drenovska K, Houivet E, Tron F, Joly P. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011;147:293-298.
41. Thoma-Uszynski S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2015;176:2015-2023.
42. Büdinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H, Merk HF, Yancey K, Hertl M. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998;102:2082-2089. (Pubitemid 29018814)
43. Lin MS, Fu CL, Giudice GJ, Olague-Marchan M, Lazaro AM, Stastny P, Diaz LA. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 2000;115:955-961. (Pubitemid 32037435)
44. Schmidt E, Ambach A, Bastian B, Bröcker EB, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. J Am Acad Dermatol 1996;34:310-312. (Pubitemid 26064011)
45. Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker EB, ZillikensD. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996;288:353-357. (Pubitemid 26232085)
46. Schmidt E, Mittnacht A, Schomig H, Dummer R, Bröcker EB, Zillikens D. Detection of IL-1 alpha, IL-1 beta and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. J Dermatol Sci 1996;11:142-147.
47. Ameglio F, D'Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationships with disease intensity. Br J Dermatol 1998;138:611-614. (Pubitemid 28212243)
48. Inaoki M, Takehara K. Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid. J Dermatol Sci 1998;16:152-157. (Pubitemid 128771613)
49. D'Auria L, Bonifati C, Cordiali-Fei P, Leone G, Picardo M, PietravalleM, Giacalone B, Ameglio F. Increased seruminterleukin-15 levels in bullous skin diseases: Correlation with disease intensity. Arch Dermatol Res 1999;291:354-356. (Pubitemid 29281325)
50. Wakugawa W, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, Yamada H, Hirai K, Tamaki K, Furue M. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: Correlation with tissue eosinophilia. Br J Dermatol 2000;143:112-116. (Pubitemid 30485253)
51. Frezzolini A, Teofoli P, Cianchini G, Barduagni S, Ruffelli M, Ferranti G, Puddu P, Pita OD. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur J Dermatol 2002;12:27-31. (Pubitemid 34131135)
52. Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, De Pita O. Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol 2004;137:595-600. (Pubitemid 39128089)
53. Gounni Abdelilah S, Wellemans V, Agouli M, Guenounou M, Hamid Q, Beck LA, Lamkhioued B. Increased expression of Th2-associated chemokines in bullous pemphigoid disease: Role of eosinophils in the production and release of these chemokines. Clin Immunol 2006;120:220-231. (Pubitemid 44080677)
54. Günther C, Carballido-Perrig N, Kopp T, Carballido JM, Pfeiffer C. CCL18 is expressed in patients with bullous pemphigoid and parallels disease course. Br J Dermatol 2009; 160:747-755.
55. Ludwig RJ, Schmidt E. Cytokines in autoimmune bullous skin diseases: Epiphenomena or contribution to pathogenesis? G Ital Dermatol Venereol 2009;144:339-349.
56. Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: Remission of disease is associated with increased frequency of interleukin-10-producing cells. J Invest Dermatol 2001;117: 1097-1102. (Pubitemid 34205903)
57. + regulatory T cells in bullous pemphigoid. Exp Dermatol 2007;16:13-21. (Pubitemid 44890346)
58. Oswald E, Fisch P, Jakob T, Bruckner-Tuderman L, Martin SF, Rensing-Ehl A. Reduced numbers of circulating gammadelta T cells in patients with bullous pemphigoid. Exp Dermatol 2009;18:991-993.
59. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007;33: 67-77. (Pubitemid 351514141)
60. Bieber K, Sun S, Ishii N, Kasperkiewicz M, Schmidt E, Hirose M, Westermann J, Yu X, Zillikens D, Ludwig RJ. Animal models for autoimmune bullous dermatoses. Exp Dermatol 2010;19:2-11.
61. Schmidt E, Reimer S, Kruse N, Jainta S, Bröcker EB, Marinkovich MP, Giudice GJ, Zillikens D. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000;115:842-848.
62. Iwata H, Kamio N, Aoyama Y, Yamamoto Y, Hirako Y, Owaribe K, Kitajima Y. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009;129: 919-926.
63. Gammon WR, Merritt CC, Lewis DM, Sams WM, Jr, Carlo JR, Wheeler CE, Jr. An in vitro model of immune complexmediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol 1982;78:285-290. (Pubitemid 12142982)
64. Sitaru C, Schmidt E, Petermann S, Munteanu LS, Bröcker EB, Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002;118:664-671. (Pubitemid 34309987)
65. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993;92:2480-2488. (Pubitemid 23333558)
66. Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995;95:1539-1544.
67. Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, Till GO, Diaz LA. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997;100: 1256-1263. (Pubitemid 27386312)
68. Chen R, Ning G, Zhao ML, Fleming MG, Diaz LA,Werb Z, Liu Z. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001;108: 1151-1158. (Pubitemid 32995373)
69. Oikarinen AI, Zone JJ, Ahmed AR, Kiistala U, Uitto J. Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases: Comparison between dermatitis herpetiformis and bullous pemphigoid. J Invest Dermatol 1983;81:261-266. (Pubitemid 13045266)
70. Welgus HG, Bauer EA, Stricklin GP. Elevated levels of human collagenase inhibitor in blister fluids of diverse etiology. J Invest Dermatol 1986;87:592-596. (Pubitemid 17178888)
71. Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS. Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 1988;90:777-782.
72. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI. Cytotoxic proteases in blister fluid of pemphigus and pemphigoid patients. Int J Tissue React 1989; 11:195-201. (Pubitemid 20123545)
73. Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1989;125:925-930. (Pubitemid 19174689)
74. Gissler HM, Simon MM, KramerMD. Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. Br J Dermatol 1992;127:272-277.
75. Kramer MD, Reinartz J. The autoimmune blistering skin disease bullous pemphigoid: The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. J Clin Invest 1993;92: 978-983. (Pubitemid 23262422)
76. Stahle-Bäckdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 1994;93:2022-2030. (Pubitemid 24143082)
77. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 2006;139: 104-113. (Pubitemid 43177321)
78. Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001;117:1091-1096. (Pubitemid 34205902)
79. Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Bröcker EB, Opdenakker G, Zillikens D, Sitaru C. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004;204:519-527. (Pubitemid 39585950)
80. Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA,Werb Z, Senior RM. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998;188:475-482. (Pubitemid 28369137)
81. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, Fairley JA, Diaz LA. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000;105:113-123. (Pubitemid 30036393)
82. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005;115:879-887. (Pubitemid 40489392)
83. Schmidt E, Wehr B, Tabengwa EM, Reimer S, Bröcker EB, Zillikens D. Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Clin Exp Immunol 2004;135: 497-504. (Pubitemid 38297153)
84. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13: 1382-1397. (Pubitemid 29270244)
85. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000;102:647-655.
86. Zillikens D, Schmidt E, Reimer S, Chimanovitch I, Hardt-Weinelt K, Rose C, Bröcker EB, Kock M, Boehncke WH. Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. J Pathol 2001;193:117-124. (Pubitemid 32051121)
87. Olasz EB, Roh J, Yee CL, Arita K, Akiyama M, Shimizu H, Vogel JC, Yancey KB. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol 2007;127:2807-2817. (Pubitemid 350134825)
88. Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR, Sakai K, Nakamura H, Olasz E, Yancey KB, Akiyama M, Shimizu H. Humanization of autoantigen. Nat Med 2007;13:378-383. (Pubitemid 46376680)
89. Li Q, Ujiie H, Shibaki A, Wang G, Moriuchi R, Qiao HJ, Morioka H, Shinkuma S, Natsuga K, Long HA, Nishie W, Shimizu H. Human IgG1 monoclonal antibody against human collagen 17 NC16A induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010;185:7746-7755.
90. Liu Z, Sui W, Zhao M, Li Z, Li N, Thresher R, Giudice GJ, Fairley JA, Sitaru C, Zillikens D, Ning G, Marinkovich MP, Diaz LA. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008;31:331-338.
91. Ujiie H, Shibaki A, NishieW, Sawamura D,Wang G, Tateishi Y, Li Q, Moriuchi R, Qiao H, Nakamura H, Akiyama M, Shimizu H. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010;184:2166-2174.
92. Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007;127:1167-1174. (Pubitemid 46625148)
93. Fairley JA, Burnett CT, Fu CL, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: Bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007;127:2605-2611. (Pubitemid 47585071)
94. Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E, Sassolas B, Labeille B, Doutre MS, Gorin I, Pauwels C, Chosidow O, Caux F, Estève E, Dutronc Y, Sigal M, Prost C, Maillard H, Guillaume JC, Roujeau JC. Prediction of survival for patients with bullous pemphigoid: A prospective study. Arch Dermatol 2005;141:691-698. (Pubitemid 41001068)
95. Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, Manos S, Korman BD, Xia Z, Korman NJ. Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59:582-588.
96. Kelly SE,Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988;118:31-40.
97. Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K, Nishikawa T. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002;30:224-232. (Pubitemid 35351315)
98. Hofmann S, Thoma-Uszynski S, Hunziker T, Bernard P, Koebnick C, Stauber A, Schuler G, Borradori L, Hertl M. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2-and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002; 119:1065-1073. (Pubitemid 35430484)
99. Yoshida M, Hamada T, Amagai M, Hashimoto K, Uehara R, Yamaguchi K, Imamura K, Okamoto E, Yasumoto S, Hashimoto T. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006;41:21-30. (Pubitemid 43075429)
100. Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112-118. (Pubitemid 39061287)
101. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998;134: 465-469. (Pubitemid 28207630)
102. Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, Prudlo C, Pawelczyk B, Messmer EM, Schuhmann M, Sinkgraven R, Büchner L, Büdinger L, Pfeiffer C, Sticherling M, Hertl M, Kaiser HW, Meurer M, Zillikens D, Messer G. Risk factors for lethal outcome in patients with bullous pemphigoid: Low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002;138: 903-908.
103. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004;122:1091-1095. (Pubitemid 38651080)
104. Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010;CD002292.
105. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/ day. A multicenter randomized study. Ann Dermatol Venereol 1984;111:925-928. (Pubitemid 15179493)
106. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D'Incan M, Plantin P, Bedane C, Young P, Bernard P, Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl JMed 2002;346:321-327. (Pubitemid 34438839)
107. Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, Bedane C, Sparsa A, Gorin I, Picard C, Tancrede-Bohin E, Sassolas B, Lok C, Guillaume JC, Doutre MS, Richard MA, Caux F, Prost C, Plantin P, Chosidow O, Pauwels C, Maillard H, Saiag P, Descamps V, Chevrant-Breton J, Dereure O, Hellot MF, Esteve E, Bernard P. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: A multicenter randomized study. J Invest Dermatol 2009 July;129(7): 1681-1687.
108. Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B, Guillot B, Foldès-Pauwels C, Prigent F, Joly P, Cordoliani F, Salagnac V, Machet L, Aldigier JC, Crickx B, Roujeau JC. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993;129:49-53. (Pubitemid 23029669)
109. Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Bonsmann G, Luger TA. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007;143:1536-1542. (Pubitemid 350277770)
110. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994;130:753-758. (Pubitemid 24182685)
111. Schmidt E, Kraensel R, Goebeler M, Sinkgraven R, Bröcker EB, Rzany B, Zillikens D. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: A retrospective study of 62 cases. Cutis 2005;76: 205-209. (Pubitemid 41413670)
112. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: Analysis of current data. Am J Clin Dermatol 2009;10:383-396.
113. Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009;161:723-731.
114. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010;38: 186-195.
115. Schmidt E, Bröcker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008;34:56-64.
116. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-373.
117. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients. J Am Acad Dermatol 2011;65:552-558.
118. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009;123:704-705.
119. Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010;302:241-253.
120. Schmidt E, Skrobek C, Kromminga A, Hashimoto T, Messer G, Bröcker EB, Yancey KB, Zillikens D. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra-and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001;145:778-783. (Pubitemid 33078348)
121. Bédane C, McMillan JR, Balding SD, Bernard P, Prost C, Bonnetblanc JM, Diaz LA, Eady RA, Giudice GJ. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: Evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997;108:901-907. (Pubitemid 27272407)
122. Oyama N, Setterfield JF, Powell AM, Sakuma-Oyama Y, Albert S, Bhogal BS, Vaughan RW, Kaneko F, Challacombe SJ, Black MM. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: The pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154:90-98. (Pubitemid 43381326)
123. Bernard P, Prost C, Lecerf V, Intrator L, Combemale P, Bedane C, Roujeau JC, Revuz J, Bonnetblanc JM, Dubertret L. Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis. J Invest Dermatol 1990;94:630-635. (Pubitemid 20141281)
124. Calabresi V, Carrozzo M, Cozzani E, Arduino P, Bertolusso G, Tirone F, Parodi A, Zambruno G, Di Zenzo G. Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin Immunol 2007;122:207-213. (Pubitemid 46073898)
125. Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992;90:1628-1633.
126. Chan LS, Majmudar AA, Tran HH, Meier F, Schaumburg-Lever G, Chen M, Anhalt G,Woodley DT,Marinkovich MP. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997; 108:848-853. (Pubitemid 27272397)
127. Luke MC, Darling TN, Hsu R, Summers RM, Smith JA, Solomon BI, Thomas GR, Yancey KB. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol 1999;135:954-959. (Pubitemid 29382434)
128. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: Partial sequence and biochemical characterization. Proc Natl Acad Sci USA 1996;93:14714-14719. (Pubitemid 26419034)
129. Rashid KA, Gürcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006;126:2631-2636. (Pubitemid 44764047)
130. Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996; 98:1509-1518. (Pubitemid 26327858)
131. Lazarova Z, Hsu R, Briggaman RA, Yancey KB. Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice. Clin Immunol 2000;95:26-32. (Pubitemid 30202814)
132. Lazarova Z, Hsu R, Yee C, Yancey KB. Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model. J Invest Dermatol 2000;114:178-184. (Pubitemid 30195992)
133. Razzaque MS, Foster CS, Ahmed AR. Tissue and molecular events in human conjunctival scarring in ocular cicatricial pemphigoid. Histol Histopathol 2001;16:1203-1212. (Pubitemid 32994464)
134. Saw VP, Schmidt E, Offiah I, Galatowicz G, Zillikens D, Dart JK, Calder VL, Daniels JT. Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid. Am J Pathol 2011;178:187-197.
135. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS, 3rd, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, Zone JJ. The first international consensus on mucous membrane pemphigoid: Definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002;138:370-379. (Pubitemid 34226335)
136. Rose C, Schmidt E, Kerstan A, Thoma-Uszynski S, Wesselmann U, Käsbohrer U, Zillikens D, Shimanovich I. Histopathology of anti-laminin 5 mucous membrane pemphigoid. J Am Acad Dermatol 2009;61:433-440.
137. Horváth B, Niedermeier A, Podstawa E, Müller R, Hunzelmann N, Kárpáti S, Hertl M. IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis. Exp Dermatol 2010;19:648-653.
138. Leverkus M, Schmidt E, Lazarova Z, Bröcker EB, Yancey KB, Zillikens D. Antiepiligrin cicatricial pemphigoid: An underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases? Arch Dermatol 1999;135:1091-1098.
139. Egan CA, Lazarova Z, Darling TN, Yee C, CotéT, Yancey KB. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001;357:1850-1851. (Pubitemid 32539120)
140. Lazarova Z, Sitaru C, Zillikens D, Yancey KB. Comparative analysis of methods for detection of anti-laminin 5 autoantibodies in patients with anti-epiligrin cicatricial pemphigoid. J Am Acad Dermatol 2004;51:886-892. (Pubitemid 39593002)
141. Brunsting LA, Perry HO. Benign pemphigoid? A report of seven cases with chronic, scarring, herpetiformplaques about the head and neck. Arch Dermatol 1957;75:489-501.
142. Kurzhals G, Stolz W, Meurer M, Kunze J, Braun-Falco O, Krieg T. Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol 1991;127:391-395.
143. Daito J, Katoh N, Asai J, Ueda E, Takenaka H, Ishii N, Hashimoto T, Kishimoto S. Brunsting-Perry cicatricial pemphigoid associated with autoantibodies to the C-terminal domain of BP180. Br J Dermatol 2008;159:984-986.
144. Jedlickova H, Niedermeier A, Zgaz?arová S, Hertl M. Brunsting-Perry pemphigoid of the scalp with antibodies against laminin 332. Dermatology 2011;222:193-195.
145. Meyer-ter-Vehn T, Schmidt E, Zillikens D, Geerling G. Mucous membrane pemphigoid with ocular involvement. Part II: Therapy. Ophthalmologe 2008;105:405-419.
146. Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010;23:268-280.
147. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: A long-term follow-up. Ophthalmology 2004;111:1380-1382. (Pubitemid 38844838)
148. O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008; 37:575-581.
149. Shimanovich I, Bröcker EB, Zillikens D. Pemphigoid gestationis: New insights into the pathogenesis lead to novel diagnostic tools. BJOG 2002;109:970-976. (Pubitemid 35279125)
150. Morrison LH, Labib RS, Zone JJ, Diaz LA, Anhalt GJ. Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest 1988;81:2023-2026.
151. Murakami H, Amagai M, Higashiyama M, Hashimoto K, Chorzelski TP, Bhogal BS, Jenkins RE, Black MM, Zillikens D, Nishikawa T, Hashimoto T. Analysis of antigens recognized by autoantibodies in herpes gestationis: Usefulness of immunoblotting using a fusion protein representing an extracellular domain of the 180kD bullous pemphigoid antigen. J Dermatol Sci 1996;13:112-117. (Pubitemid 26389877)
152. Chimanovitch I, Schmidt E, Messer G, Döpp R, Partscht K, Bröcker EB, Giudice GJ, Zillikens D. IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis. J Invest Dermatol 1999;113:140-142. (Pubitemid 29328175)
153. Di Zenzo G, Calabresi V, Grosso F, Caproni M, Ruffelli M, Zambruno G. The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol 2007;127:864-873. (Pubitemid 46434640)
154. Herrero-González JE, Brauns O, Egner R, Rönspeck W, Mascaró JM, Jr, Jonkman MF, Zillikens D, Sitaru C. Immunoadsorption against two distinct epitopes on human type XVII collagen abolishes dermal-epidermal separation induced in vitro by autoantibodies from pemphigoid gestationis patients. Eur J Immunol 2006;36:1039-1048.
155. Döpp R, Schmidt E, Chimanovitch I, Leverkus M, Bröcker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000;42:577-583. (Pubitemid 30479879)
156. Lin MS, Gharia MA, Swartz SJ, Diaz LA, Giudice GJ. Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol 1999;162:4991-4997. (Pubitemid 29314907)
157. Sitaru C, Powell J, Messer G, Bröcker EB, Wojnarowska F, Zillikens D. Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol 2004;103:757-763. (Pubitemid 40459039)
158. Wojnarowska F, Whitehead P, Leigh IM, Bhogal BS, Black MM. Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults. Br J Dermatol 1991;124:157-162.
159. Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996;106: 734-738. (Pubitemid 26119732)
160. Zone JJ, Taylor TB, Meyer LJ, Petersen MJ. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 1998;110:207-210. (Pubitemid 28144592)
161. Zone JJ, Taylor TB, Kadunce DP, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990;85:812-820. (Pubitemid 20087485)
162. Pas HH, Kloosterhuis GJ, Heeres K, van der Meer JB, Jonkman MF. Bullous pemphigoid and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic cross-reactivity to BP180. J Invest Dermatol 1997;108:423-429. (Pubitemid 27148276)
163. Hirako Y, Usukura J, Uematsu J, Hashimoto T, Kitajima Y, Owaribe K. Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. J Biol Chem 1998;273:9711-9717. (Pubitemid 28183062)
164. Schäcke H, Schumann H, Hammami-Hauasli N, Raghunath M, Bruckner-Tuderman L. Two forms of collagen XVII in keratinocytes: A full-length transmembrane protein and a soluble ectodomain. J Biol Chem 1998;273:25937- 25943.
165. Hirako Y, Nishizawa Y, Sitaru C, Opitz A, Marcus K, Meyer HE, Butt E, Owaribe K, Zillikens D. The 97-kDa (LABD97) and 120-kDa (LAD-1) fragments of bullous pemphigoid antigen 180/type XVII collagen have different N-termini. J Invest Dermatol 2003;121:1554-1556. (Pubitemid 38005513)
166. FranzkeCW, Bruckner-Tuderman L, Blobel CP. Shedding of collagen XVII/BP180 in skin depends on both ADAM10 and ADAM9. J Biol Chem 2009;284:23386-23396.
167. Hofmann SC, Voith U, Schönau V, Sorokin L, Bruckner-Tuderman L, Franzke CW. Plasmin plays a role in the in vitro generation of the linear IgA dermatosis antigen LADB97. J Invest Dermatol 2009;129:1730-1739.
168. ZillikensD, Herzele K,GeorgiM, Schmidt E, Chimanovitch I, Schumann H,Mascaro JM, Jr, Diaz LA, Bruckner-Tuderman L, Bröcker EB, Giudice GJ. Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP180. J Invest Dermatol 1999a;113:947-953. (Pubitemid 30013336)
169. Zambruno G, Manca V, Kanitakis J, Cozzani E, Nicolas JF, Giannetti A. Linear IgA bullous dermatosis with autoantibodies to a 290 kDa antigen of anchoring fibrils. J Am Acad Dermatol 1994;31:884-888. (Pubitemid 24336187)
170. Ghohestani RF, Nicolas JF, Kanitakis J, Claudy A. Linear IgA bullous dermatosis with IgA antibodies exclusively directed against the 180-or 230-kDa epidermal antigens. J Invest Dermatol 1997;108:854-858. (Pubitemid 27272398)
171. Natsuga K, Nishie W, Shinkuma S, Moriuchi R, Shibata M, Nishimura M, Hashimoto T, Shimizu H. Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid. Br J Dermatol 2010;162:513-517.
172. Kromminga A, Scheckenbach C, Georgi M, Hagel C, Arndt R, Christophers E, Bröcker EB, Zillikens D. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun 2000;15:293-300.
173. Mulyowa GK, Jaeger G, Kabakyenga J, Bröcker EB, Zillikens D, Schmidt E. Autoimmune subepidermal blistering diseases in Uganda: Correlation of autoantibody class with age of patients. Int J Dermatol 2006;45:1047-1052. (Pubitemid 44317117)
174. Zone JJ, Egan CA, Taylor TB, Meyer LJ. IgA autoimmune disorders: Development of a passive transfer mouse model. J Investig Dermatol Symp Proc 2004;9:47-51. (Pubitemid 38096198)
175. Guide SV, Marinkovich MP. Linear IgA bullous dermatosis. Clin Dermatol 2001;19:719-727. (Pubitemid 33036850)
176. Kasperkiewicz M, Meier M, Zillikens D, Schmidt E. Linear IgA disease: Successful application of immunoadsorption and review of the literature. Dermatology 2010;220: 259-263.
177. Willsteed E, Bhogal BS, Das AK,Wojnarowska F, BlackMM, McKee PH. Lichen planus pemphigoides: A clinicopathological study of nine cases. Histopathology 1991;19:147-154.
178. Davis AL, Bhogal BS, Whitehead P, Frith P, Murdoch ME, Leigh IM, Wojnarowska F. Lichen planus pemphigoides: Its relationship to bullous pemphigoid. Br J Dermatol 1991;125: 263-271.
179. Bouloc A, Vignon-Pennamen MD, Caux F, Teillac D, Wechsler J, Heller M, LebbéC, Flageul B, Morel P, Dubertret L, Prost C. Lichen planus pemphigoides is a heterogeneous disease: A report of five cases studied by immunoelectron microscopy. Br J Dermatol 1998;138: 972-980. (Pubitemid 28293961)
180. ZillikensD, Caux F, Mascaro JM,WesselmannU, Schmidt E, Prost C, Callen JP, Bröcker EB, Diaz LA, Giudice GJ. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999b;113:117-121. (Pubitemid 29328169)
181. ZillikensD, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, Liu Z, Giudice GJ, Tran HH, Marinkovich MP, Brocker EB, Hashimoto T. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996;106:1333-1338. (Pubitemid 26194248)
182. Dainichi T, Kurono S, Ohyama B, Ishii N, Sanzen N, Hayashi M, Shimono C, Taniguchi Y, Koga H, Karashima T, Yasumoto S, Zillikens D, Sekiguchi K, Hashimoto T. Antilaminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009;106:2800-2805.
183. Groth S, Recke A, Vafia K, Ludwig RJ, Hashimoto T, Zillikens D, Schmidt E. Development of a simple enzymelinked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011;164: 76-82.
184. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. Laminin -A glycoprotein from basement membranes. J Biol Chem 1979;254:9933-9937.
185. Dainichi T, Koga H, Tsuji T, Ishii N, Ohyama B, Ueda A, Natsuaki Y, Karashima T, Nakama T, Yasumoto S, Zillikens D, Hashimoto T. From anti-p200 pemphigoid to antilaminin gamma1 pemphigoid. J Dermatol 2010;37:231-238.
186. Iwata H, Hiramitsu Y, Aoyama Y, Kitajima Y. A case of antip200 pemphigoid: Evidence for a different pathway in neutrophil recruitment compared with bullous pemphigoid. Br J Dermatol 2009;160:462-464.
187. Dilling A, Rose C, Hashimoto T, Zillikens D, Shimanovich I. Anti-p200 pemphigoid: A novel autoimmune subepidermal blistering disease. J Dermatol 2007;34:1-8. (Pubitemid 46005950)
188. Rose C, Weyers W, Denisjuk N, Hillen U, Zillikens D, Shimanovich I. Histopathology of anti-p200 pemphigoid. Am J Dermatopathol 2007;29:119-124. (Pubitemid 46573078)
189. Kasperkiewicz M, Hoppe U, Zillikens D, Schmidt E. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol 2010;35:614.